The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Sung, Hyuna ^a   Choi, Ji Yeob ^a   Lee, Sang Ah ^b   Lee, Kyoung Mu ^c   Han, Sohee ^a   Jeon, Sujee ^d   Song, Minkyo ^a   Lee, Yunhee ^a   Park, Sue K ^a   Yoo, Keun Young ^a   Noh, Dong Young ^a   Ahn, Sei Hyun ^e   Kang, Daehee ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Kangwon National University College of Medicine   (South Korea)

^c Korea National Open University   (South Korea)

^d Seoul National University   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GELATINASE B; HORMONE RECEPTOR BLOCKING AGENT; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREOPERATIVE EVALUATION; PROTEIN BLOOD LEVEL; RISK REDUCTION;

ACUTE-PHASE PROTEINS; ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LIPOCALINS; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE PERIOD; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; RISK FACTORS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84861442155     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-193     Document Type: Article

References (47)

1. Hery C, Ferlay J, Boniol M, Autier P. Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. Ann Oncol 2008, 19:1187-1194. 10.1093/annonc/mdn025, 18325921.
2. Hery C, Ferlay J, Boniol M, Autier P. Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. Ann Oncol 2008, 19:1009-1018. 10.1093/annonc/mdm593, 18296422.
3. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312. 10.1200/JCO.2007.14.2364, 17954709.
4. Bolignano D, Donato V, Lacquaniti A, Fazio MR, Bono C, Coppolino G, Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett 2010, 288:10-16. 10.1016/j.canlet.2009.05.027, 19540040.
5. Yang J, Moses MA. Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle 2009, 8:2347-2352. 10.4161/cc.8.15.9224, 3381736, 19571677.
6. Leng X, Wu Y, Arlinghaus RB. Relationships of lipocalin 2 with breast tumorigenesis and metastasis. J Cell Physiol 2011, 226:309-314. 10.1002/jcp.22403, 20857428.
7. Triebel S, Blaser J, Reinke H, Tschesche H. A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett 1992, 314:386-388. 10.1016/0014-5793(92)81511-J, 1281792.
8. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993, 268:10425-10432.
9. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001, 276:37258-37265. 10.1074/jbc.M106089200, 11486009.
10. Tschesche H, Zolzer V, Triebel S, Bartsch S. The human neutrophil lipocalin supports the allosteric activation of matrix metalloproteinases. Eur J Biochem 2001, 268:1918-1928. 10.1046/j.1432-1327.2001.02066.x, 11277914.
11. Fernandez CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 2005, 11:5390-5395. 10.1158/1078-0432.CCR-04-2391, 16061852.
12. Tsai HT, Su PH, Lee TH, Tee YT, Lin LY, Yang SF, Wang PH. Significant elevation and correlation of plasma neutrophil gelatinase associated lipocalin and its complex with matrix metalloproteinase-9 in patients with pelvic inflammatory disease. Clin Chim Acta 2011, 412:1252-1256. 10.1016/j.cca.2011.03.021, 21439274.
13. Gupta K, Shukla M, Cowland JB, Malemud CJ, Haqqi TM. Neutrophil gelatinase-associated lipocalin is expressed in osteoarthritis and forms a complex with matrix metalloproteinase 9. Arthritis Rheum 2007, 56:3326-3335. 10.1002/art.22879, 17907186.
14. Diamanti-Kandarakis E, Livadas S, Kandarakis SA, Margeli A, Papassotiriou I. Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism?. Eur J Endocrinol 2008, 158:525-531. 10.1530/EJE-07-0822, 18362300.
15. Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 2008, 14:2378-2386. 10.1158/1078-0432.CCR-07-1253, 18413828.
16. Provatopoulou X, Gounaris A, Kalogera E, Zagouri F, Flessas I, Goussetis E, Nonni A, Papassotiriou I, Zografos G. Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer 2009, 9:390. 10.1186/1471-2407-9-390, 2775750, 19889214.
17. Stoesz SP, Friedl A, Haag JD, Lindstrom MJ, Clark GM, Gould MN. Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int J Cancer 1998, 79:565-572. 10.1002/(SICI)1097-0215(19981218)79:6<565::AID-IJC3>3.0.CO;2-F, 9842963.
18. Han S, Lee KM, Choi JY, Park SK, Lee JY, Lee JE, Noh DY, Ahn SH, Han W, Kim DH, et al. CASP8 polymorphisms, estrogen and progesterone receptor status, and breast cancer risk. Breast Cancer Res Treat 2008, 110:387-393. 10.1007/s10549-007-9730-5, 17940865.
19. Verweij PJ, Van Houwelingen HC. Cross-validation in survival analysis. Stat Med 1993, 12:2305-2314. 10.1002/sim.4780122407, 8134734.
20. Noh JM, Choi DH, Huh SJ, Park W, Yang JH, Nam SJ, Im YH, Ahn JS. Patterns of recurrence after breast-conserving treatment for early stage breast cancer by molecular subtype. J Breast Cancer 2011, 14:46-51. 10.4048/jbc.2011.14.1.46, 3148515, 21847394.
21. Choi KM, Kim TN, Yoo HJ, Lee KW, Cho GJ, Hwang TG, Baik SH, Choi DS, Kim SM. Effect of exercise training on A-FABP, lipocalin-2 and RBP4 levels in obese women. Clin Endocrinol (Oxf) 2009, 70:569-574.
22. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. NGAL (neutrophil gelatinase-associated lipocalin) is a new and sensitive marker of kidney function in renal allograft recipients. Transpl Int 2007, 20:240-240.
23. Porta C, Paglino C, De Amici M, Quaglini S, Sacchi L, Imarisio I, Canipari C. Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int 2010, 77:809-815. 10.1038/ki.2009.552, 20147887.
24. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009, 54:1012-1024. 10.1053/j.ajkd.2009.07.020, 19850388.
25. Choi KM, Lee JS, Kim EJ, Baik SH, Seo HS, Choi DS, Oh DJ, Park CG. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J Endocrinol 2008, 158:203-207. 10.1530/EJE-07-0633, 18230827.
26. Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, Xu XC. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 2008, 122:2050-2056. 10.1002/ijc.23337, 18172859.
27. Mannello F, Tonti GA. Gelatinase concentrations and zymographic profiles in human breast cancer: matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: the coagulation/fibrinolysis pathways alter the release, activation and recovery of different gelatinases in serum. Int J Cancer 2007, 121:216-218. author reply 219-223, 10.1002/ijc.22652, 17315186.
28. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 2008, 108:389-397. 10.1007/s10549-007-9619-3, 17554627.
29. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, Strong RK, Zurakowski D, Moses MA. Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci U S A 2009, 106:3913-3918. 10.1073/pnas.0810617106, 2656179, 19237579.
30. Sabo E, Meitner PA, Tavares R, Corless CL, Lauwers GY, Moss SF, Resnick MB. Expression analysis of Barrett's esophagus-associated high-grade dysplasia in laser capture microdissected archival tissue. Clin Cancer Res 2008, 14:6440-6448. 10.1158/1078-0432.CCR-08-0302, 2701739, 18927283.
31. Kubben FJ, Sier CF, Hawinkels LJ, Tschesche H, van Duijn W, Zuidwijk K, van der Reijden JJ, Hanemaaijer R, Griffioen G, Lamers CB, Verspaget HW. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer 2007, 43:1869-1876. 10.1016/j.ejca.2007.05.013, 17604154.
32. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 2004, 112:14-25. 10.1002/ijc.20408, 15305371.
33. Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P, Sauvanet A, Lemoine NR. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol 2002, 160:1745-1754. 10.1016/S0002-9440(10)61121-2, 1850868, 12000726.
34. Wang HJ, He XJ, Ma YY, Jiang XT, Xia YJ, Ye ZY, Zhao ZS, Tao HQ. Expressions of neutrophil gelatinase-associated lipocalin in gastric cancer: a potential biomarker for prognosis and an ancillary diagnostic test. Anat Rec (Hoboken) 2010, 293:1855-1863.
35. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 2002, 10:1033-1043. 10.1016/S1097-2765(02)00708-6, 12453412.
36. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, Aderem A. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004, 432:917-921. 10.1038/nature03104, 15531878.
37. Somiari SB, Somiari RI, Heckman CM, Olsen CH, Jordan RM, Russell SJ, Shriver CD. Circulating MMP2 and MMP9 in breast cancer - potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer 2006, 119:1403-1411. 10.1002/ijc.21989, 16615109.
38. Decock J, Hendrickx W, Wildiers H, Christiaens MR, Neven P, Drijkoningen M, Paridaens R. Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables. Clin Exp Metastasis 2005, 22:495-502. 10.1007/s10585-005-3992-2, 16320112.
39. Talvensaari-Mattila A, Turpeenniemi-Hujanen T. Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma. Cancer Lett 2005, 217:237-242. 10.1016/j.canlet.2004.06.056, 15617842.
40. Somiari SB, Shriver CD, Heckman C, Olsen C, Hu H, Jordan R, Arciero C, Russell S, Garguilo G, Hooke J, Somiari RI. Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Lett 2006, 233:98-107. 10.1016/j.canlet.2005.03.003, 16473671.
41. Patel S, Sumitra G, Koner BC, Saxena A. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression. Clin Biochem 2011, 44:869-872. 10.1016/j.clinbiochem.2011.04.019, 21565179.
42. La Rocca G, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 2004, 90:1414-1421. 10.1038/sj.bjc.6601725, 2409673, 15054465.
43. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 2005, 23:1370-1378. 10.1200/JCO.2005.01.079, 15684320.
44. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002, 20:1128-1143. 10.1200/JCO.20.4.1128, 11844838.
45. Rosen PR, Groshen S, Saigo PE, Kinne DW, Hellman S. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 1989, 7:355-366.
46. Yip CH, Taib NA, Tan GH, Ng KL, Yoong BK, Choo WY. Predictors of axillary lymph node metastases in breast cancer: is there a role for minimal axillary surgery?. World J Surg 2009, 33:54-57. 10.1007/s00268-008-9782-7, 18958521.
47. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989, 63:181-187. 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H, 2910416.